易瑞生物控股股东减持完成，实际控制人股份质押变动

Core Viewpoint - The company has completed a share reduction plan by its controlling shareholder, is advancing a collaboration agreement with Chr. Hansen, and is expanding its pet health business while accelerating its international strategy [1]. Share Reduction Plan - On February 2, 2026, the company announced that its controlling shareholder, Yirui Venture Capital, and its concerted parties completed a share reduction plan, reducing a total of 10.68 million shares, accounting for 2.64% of the total share capital. The reduction was conducted through centralized bidding and block trading, with a price range of 8.81 to 9.85 yuan per share. The company stated that the reduction would not affect control or operational stability, and the plan has reached its deadline [2]. Share Pledge Changes - On the same day, the actual controller, Zhu Hai, released a pledge of 4.4 million shares (accounting for 7.31% of his holdings) and re-pledged the same number of shares for personal funding needs. The announcement indicated that the pledge risk is controllable, with no risk of forced liquidation [3]. Contract Progress - A significant cooperation agreement signed with global biotechnology company Chr. Hansen in April 2025 became effective on June 16, 2025, with a term from 2025 to 2029 and a total sales target of approximately 73.06 million euros (about 600 million yuan). The company reported that the collaboration is progressing smoothly and will support overseas business expansion [4]. Business Development - The company plans to extend its reach into high-potential areas such as pet geriatric disease prevention and pet vaccines, with related business currently in the strategic layout phase. The company will announce timely updates if it meets disclosure standards [5]. Performance Strategy - The financial report for the first three quarters of 2025 shows that the company achieved an operating income of 186 million yuan (a year-on-year increase of 17.45%) and a net profit attributable to shareholders of 18 million yuan (a significant year-on-year increase of 362.49%). International business expansion has become a key focus, with the company accelerating its international layout through global cooperation [6].